|
Feb 8
|
Weight loss drugs make patients lose muscle mass, says AstraZeneca chief
|
|
Feb 8
|
AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down
|
|
Feb 8
|
UPDATE 2-Astrazeneca says Catalent deal shows need for in-house capacity
|
|
Feb 8
|
Astrazeneca says Catalent deal shows need for in-house capacity
|
|
Feb 8
|
UPDATE 2-European shares edge lower as healthcare losses overpower earnings-fuelled rally
|
|
Feb 8
|
UPDATE 2-FTSE 100 retreats as AstraZeneca earnings disappoint
|
|
Feb 8
|
London Stocks Edge Up as BAT, Unilever Gain After Earnings Updates; AstraZeneca Falls
|
|
Jan 27
|
3 Magnificent Stocks to Buy and Hold Forever
|
|
Jan 25
|
24 Least Developed Countries in Europe in 2024
|
|
Jan 25
|
PRESS DIGEST-British Business - Jan 25
|
|
Jan 22
|
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
|
|
Jan 22
|
Gilead Stock Tumbles on Cancer Drug Disappointment
|
|
Jan 22
|
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
|
|
Jan 22
|
Gilead Sinks After Lung Cancer Drug Fails to Improve Survival
|
|
Jan 22
|
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
|
|
Jan 22
|
BioNTech challenges AstraZeneca with breast cancer precision drug trial
|
|
Jan 22
|
The Zacks Analyst Blog Highlights Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific
|
|
Jan 21
|
The total return for AstraZeneca (LON:AZN) investors has risen faster than earnings growth over the last five years
|
|
Jan 19
|
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
|
|
Jan 19
|
Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca
|